25周年を記念 1999-2024
*3年間で¥ 153396、たったの¥ 61358
フォローフィードコミュニティでトレーダーや投資家とつながりましょう.
包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.
ターミナル モニターで株式と資産のウォッチリストを整理および監視します
Disclosure of notification received from FMR LLC Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 26 November 2024 – 6.45 PM...
Fagron reports outstanding third quarter 2024 performance with 12.1% revenue growth and reaffirms full-year outlook Regulated information - inside...
Disclosure of notification received from AOC Pharma S.à r.l. Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 8 October 2024...
Fagron completes share buy-back program Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 13 September 2024 – 6PM CET Fagron...
Fagron’s share buy-back program: Weekly update Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 6 September 2024 – 6PM CET...
Fagron’s share buy-back program: Weekly update Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 30 August 2024 – 6PM CET...
Fagron’s share buy-back program: Weekly update Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 23 August 2024 – 6PM CET...
Fagron delivers strong performance with 16% topline growth and 17% increase in REBITDA for the first half of 2024 Regulated information - inside...
Fagron shareholders approve all voting items at AGM and EGM Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 13 May 2024...
Fagron publishes agenda for 2024 annual shareholders meeting and extraordinary general meeting Regulated information Nazareth...
Record revenue of €209 million in first quarter reflecting 15% topline growth Regulated information - inside informationNazareth...
Disclosure notification from Mawer Investment Management Ltd. Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 19 March...
Fagron publishes annual report 2023 Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 14 March 2024 – 6:30 PM CET Fagron...
Fagron delivers strong performance with 12% topline growth and 14% increase in REBITDA for FY 2023 Regulated information – inside...
Disclosure notification from AOC Pharma S.à r.l. – passing 10% threshold Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands...
ご覧いただいた銘柄が下記のボックス内に表示されますので、過去閲覧した銘柄情報に簡単にアクセスすることができます。
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約